The Claim
In individuals with obesity and prediabetes, pharmacologic GLP-1 receptor agonism with liraglutide produces metabolic effects that are not replicated by DPP-4 inhibition with sitagliptin, despite comparable increases in active GLP-1 and GIP levels.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with obesity and prediabetes, the drug liraglutide affects metabolism in a way that cannot be achieved by another drug, sitagliptin, even though both drugs raise the same levels of GLP-1 and GIP hormones.
See the scientific wording
In individuals with obesity and prediabetes, the insulin-sensitizing effect of liraglutide is not replicated by increasing endogenous GLP-1 via DPP-4 inhibition with sitagliptin, despite comparable increases in active GLP-1 and GIP levels, indicating that pharmacologic GLP-1R agonism has unique metabolic effects.
Liraglutide sticks tightly to the GLP-1 receptor and keeps it turned on for a long time, which directly improves how the liver and muscles respond to insulin. Sitagliptin only makes the body produce more of the natural hormone, but that hormone doesn't stay active long enough or bind strongly enough to trigger the same metabolic changes.
What the research says
1 studyLiraglutide directly activates a hormone receptor to improve insulin sensitivity, even before weight loss, but sitagliptin—though it makes more of the same hormone—doesn’t help insulin sensitivity at all. So, just making more of the hormone isn’t enough; you need to directly turn on the receptor.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.